5555-72-6Relevant academic research and scientific papers
INHIBITORS OF DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1B
-
Page/Page column 152-153, (2021/04/10)
The present invention relates to compounds of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof (I), in particular for use in the treatment, amelioration or prevention of cancer, Alzheimer, Parkinson, Down syndrome, Metabolic syndrome, Diabetes and/or osteoarthritis.
ENOLASE INHIBITORS AND METHODS OF TREATMENT THEREWITH
-
Paragraph 00157, (2016/09/26)
Provided herein are compounds of the formula (I) wherein the variables R1, R2, R3, R4, X1, X2, Y1, and A1 are as defined herein. Such compounds may be used, for exampl
Reactions of N-benzyloxycarbamate derivatives with stabilized carbon nucleophiles: A new synthetic approach to polyhydroxamic acids and other hydroxamate-containing mixed ligand systems
Liu, Yuan,Jacobs, Hollie K.,Gopalan, Aravamudan S.
supporting information; experimental part, p. 782 - 788 (2009/07/11)
Hydroxamic acids are an important class of chelators of hard metal ions such as Fe(III), which have found applications in therapeutic, diagnostic, and separation chemistry. Hence, methods for their preparation and incorporation into various matrices are i
